Reimagining the RNA manufacturing space: An interview with ReciBioPharm’s leaders

The COVID-19 pandemic catapulted RNA therapies into the spotlight, revealing their potential to revolutionise healthcare. While the biopharma industry's manufacturing capacity has grown exponentially, the next challenge is clear: innovation.

In a recent interview with Life Science Knowledge Hub at BIO 2024, Daniel Spurgin, Director of Strategic Partnerships at ReciBioPharm, emphasised the need for flexibility, transparency and cutting-edge solutions in RNA manufacturing. According to Chief Scientific Officer, Aaron Cowley, ReciBioPharm is leading this charge by developing an AI-driven, continuous manufacturing platform that promises to produce mRNA, saRNA, and circular RNA faster and at a lower cost.

This groundbreaking technology, a collaboration with the Massachusetts Institute of Technology (MIT) and funded by the US Food and Drug Administration (FDA), could transform the RNA landscape, making therapies more accessible and affordable while ensuring preparedness for future health crises.

In the interview, Spurgin highlighted: “The next generation of therapies shouldn't be made on outdated manufacturing lines. We're building the platform of the future - our continuous process, which is expected to be CGMP-compliant by next year. We also support clients who prefer traditional batch processes, offering expertise, transparency and a full suite of cGMP capabilities.” 

Want to learn more about the future of RNA manufacturing? 
Watch the full interview with Daniel Spurgin and Aaron Cowley to get an exclusive look at ReciBioPharm's vision for the future of RNA.